First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Humana Inc.

    HUM · 26 developments mapped · last assessed 2026-09-18

    Market Ontology has mapped 26 macro, policy, and market developments to Humana Inc. since 2026-09-05. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for HUM yet, so no modelled value is shown. The HUM valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run HUM on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for HUM. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Centene improves Medicare health benefit ratio to 89.5% amid footprint reset

      Sector-wide sentiment improvement due to positive operational signals from a peer, suggesting broader industry trends.

      · Moves sector profitability outlook, investor sentiment towards managed care

    • Main threat

      Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline

      Second-order effect; industry-wide Medicaid enrollment trends could impact HUM's Medicaid segment, though less dominant than Medicare.

      · Moves medicaid membership growth rates, segment specific medical loss ratio (mlr)

    • Open question

      Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%

      As a major Medicare Advantage provider, Humana is directly exposed to the 'ongoing margin repricing across the managed care complex' and regulatory changes affecting MLR and profitability.

      · Moves profitability outlook for medicare advantage, regulatory risk premium

    What changed, by assumption

    Sector profitability outlook
    • 2026-09-12Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
    Profitability outlook for medicare advantage
    • 2026-09-12Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
    Peer multiples
    • 2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3%, Lifting 2026 EPS Consensus by 21%
    Competitive intensity
    • 2026-09-12Centene trims Medicare health benefits ratio to 89.5% aiming for 2027 breakeven
    Profitability margins
    • 2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3% as 2026 EPS Consensus Rises 21%

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-07-09MarginBearishIdentified by HHS OIG for high denial rates in post-acute prior authorization, increasing regulatory risk for MA-heavy insurers.0.75

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-18Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid Shrinkagewatch3-12m0.40
    2026-09-18Centene posts $2.51 Q2 EPS as Medicaid rolls shrink 8%-9% in 2026watch3-12m0.40
    2026-09-18Centene posts Q2 adjusted EPS of $2.51 amid 8%-9% projected Medicaid roll-offwatch3-12m0.30
    2026-09-18Centene Delivers $2.51 Q2 EPS as Commercial Margins Offset 9% Medicaid Declinewatch1-3m0.30
    2026-09-18Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 declineBearish3-12m0.30
    2026-09-18Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Dropwatch3-12m0.40
    2026-09-18Centene posts Q2 EPS turnaround to $2.51 as Medicaid rolls off 8% to 9%watch3-12m0.30
    2026-09-16Oscar Health, Inc. Raises Full Year 2026 Earnings Guidancewatch3-12m0.20
    2026-09-16Centene Corporation Reaffirms Full Year 2026 EPS Guidancewatch1-3m0.30
    2026-09-14Centene Restructures Medicare Advantage Footprint to Target 2027 Margin Breakevenmixed3-12m0.40
    2026-09-13Centene Improves Medicare HBR to 89.5% via Footprint Simplificationmixed3-12m0.40
    2026-09-13Centene Targets 2027 Medicare Advantage Breakeven as Health Benefit Ratio Hits 89.5%mixed3-12m0.30